Added 1 day ago Drug news

FDA approves Kalydeco to treat cystic fibrosis in children aged 12 to <24 months.- Vertex Pharma.

Vertex Pharmaceuticals Incorporated announced the FDA approved Kalydeco (ivacaftor) to include use in children with cystic fibrosis (CF) ages 12...

Added 9 days ago Drug news

FDA approves Orkambi to include use in children ages 2 through 5 years with cystic fibrosis who have two copies of the F508del-CFTR mutation.- Vertex Pharma.

Vertex Pharmaceuticals Incorporated announced the FDA has approved Orkambi (lumacaftor/ivacaftor) to include use in children ages 2 through 5 years...

Added 19 days ago Drug news

CHMP recommends Symkevi + Kalydeco to treat children with cystic fibrosis aged 12 and older.- Vertex.

Vertex Pharmaceuticals (Europe) Limited, announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a...

Cystic fibrosis: diagnosis and management

This guideline covers diagnosing and managing cystic fibrosis. It specifies how to monitor the condition and manage the symptoms to improve quality of life.

Added 2 months ago

European Cystic Fibrosis Society Standards of Care: Best Practice guidelines

Specialised CF care has led to a dramatic improvement in survival in CF: in the last four decades, well above what was seen in the general population over the same period.

Added 4 years ago

End of life care for patients with cystic fibrosis

Palliative care is an approach that improves quality of life for patients and their families facing problems associated with a life-threatening illness. Care planning is particularly important in CF...

Added 7 years ago

Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study.

Background: Ivacaftor is generally safe and effective in patients aged 2 years and older who have cystic fibrosis and specific CFTR mutations. We assessed its use in children aged 12 to <24 months.

Added 1 month ago

Investigation of the effects of the CFTR potentiator ivacaftor on human P-glycoprotein (ABCB1).

Added 6 months ago

Ivacaftor restores CFTR-dependent sweat gland fluid secretion in cystic fibrosis subjects with S945L alleles.

Background: To determine in vivo effects of CFTR modulators on mutation S945L.

Added 6 months ago